Stockscreener 앱 받기
21.53
14.36%
-3.61
시장 영업 전:
21.54
0.010
+0.05%
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com UK
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com Canada
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView — Track All Markets
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView — Track All Markets
Gilead, Arcus scrap late-stage trial of cancer drug combo - Yahoo
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $431,000 Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 82,997 Shares of Stock - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Acquired by Tema Etfs LLC - MarketBeat
Arcus Biosciences (NYSE:RCUS) Downgraded by Wall Street Zen to Sell - MarketBeat
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Can Arcus Biosciences Inc. stock ride next bull market cycleShort Setup & Real-Time Market Trend Scan - Newser
Decheng Capital LLC Has $1.30 Million Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
How Arcus Biosciences Inc. stock performs during market turbulenceJuly 2025 Review & Weekly High Potential Alerts - Newser
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Earnings Overview Report & Safe Entry Momentum Stock Tips - Newser
How Arcus Biosciences Inc. stock behaves in tightening cyclesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
RCUS: Casdatifan shows superior efficacy in RCC, with pivotal trials and strong financial backing - TradingView
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Purchased by Geode Capital Management LLC - MarketBeat
How Arcus Biosciences Inc. stock compares with market leadersJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares - MarketBeat
Arcus Biosciences stock hits 52-week high at 26.32 USD By Investing.com - Investing.com Australia
Arcus Biosciences stock hits 52-week high at 26.32 USD - Investing.com
SG Americas Securities LLC Buys 17,111 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
1.08%
0.91%
자본화:
|
볼륨(24시간):